Quarterly report pursuant to Section 13 or 15(d)

Organization and Nature of Business (Details)

v3.22.2
Organization and Nature of Business (Details)
3 Months Ended 6 Months Ended
Jun. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Jun. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Jun. 30, 2022
USD ($)
segment
Jun. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Subsidiary, Sale of Stock [Line Items]              
Number of operating segments | segment         1    
Net loss $ 3,667,255 $ 3,960,308 $ 4,282,962 $ 3,056,033 $ 7,627,563 $ 7,338,995  
Net cash used in operating activities         6,313,144 $ 7,862,670  
Accumulated deficit $ 51,552,936       $ 51,552,936   $ 43,925,373
Minimum              
Subsidiary, Sale of Stock [Line Items]              
period in which the company has to raise additional capital to complete clinical development         6 months    
Maximum              
Subsidiary, Sale of Stock [Line Items]              
period in which the company has to raise additional capital to complete clinical development         9 months